Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2018-03-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/17460441.2018.1455660PMID 29566560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacterial lipoproteins; biogenesis, sorting and quality control.

  2017cited by this paper
• Synergy between Active Efflux and Outer Membrane Diffusion Defines Rules of Antibiotic Permeation into Gram-Negative Bacteria

  2017cited by this paper
• Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model

  2017cited by this paper
• Pharmaceutical Approval Update.

  2017cited by this paper
• Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance

  2017cited by this paper
• Erratum: Unusual marine unicellular symbiosis with the nitrogen-fixing cyanobacterium UCYN-A

  2017cited by this paper
• Delafloxacin: First Global Approval

  2017cited by this paper
• Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design.

  2017cited by this paper
• Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD.

  2017cited by this paper
• Delafloxacin: design, development and potential place in therapy

  2017influential reference
• Predictive compound accumulation rules yield a broad-spectrum antibiotic

  2017cited by this paper
• Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane

  2017cited by this paper
• Surface-Exposed Lipoproteins: An Emerging Secretion Phenomenon in Gram-Negative Bacteria.

  2016cited by this paper
• Are the physicochemical properties of antibacterial compounds really different from other drugs?

  2016cited by this paper
• Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials.

  2016cited by this paper
• Multidrug efflux pumps of Gram-positive bacteria.

  2016cited by this paper
• Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial peptides.

  2016cited by this paper
• Targeting human pathogenic bacteria by siderophores: A proteomics review.

  2016cited by this paper
• Bacterial Multidrug Efflux Pumps: Much More Than Antibiotic Resistance Determinants

  2016cited by this paper
• A Gestalt approach to Gram-negative entry.

  2016influential reference
• Nanotechnology approaches for antibacterial drug delivery: Preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid.

  2015cited by this paper
• Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It.

  2015cited by this paper
• Molecular Simulations of Gram-Negative Bacterial Membranes: A Vignette of Some Recent Successes.

  2015cited by this paper
• A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.

  2015cited by this paper
• Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections.

  2014cited by this paper
• The mycobacterial cell envelope-lipids.

  2014cited by this paper
• Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations.

  2014cited by this paper
• Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them

  2014cited by this paper
• Which Three-Dimensional Characteristics Make Efficient Inhibitors of Protein-Protein Interactions?

  2014cited by this paper
• Structure of the AcrAB-TolC multidrug efflux pump

  2014cited by this paper
• Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides

  2014cited by this paper
• Siderophores as “Trojan Horses”: tackling multidrug resistance?

  2014cited by this paper
• General Platform for Systematic Quantitative Evaluation of Small-Molecule Permeability in Bacteria

  2014cited by this paper
• Pharmaceutical approval update.

  2013cited by this paper
• Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus

  2013cited by this paper
• The intrinsic resistome of bacterial pathogens

  2013cited by this paper
• Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily

  2013cited by this paper
• Microbial siderophores: a mini review

  2013cited by this paper
• Siderophore conjugates

  2013cited by this paper
• The Efflux Inhibitor Phenylalanine-Arginine Beta-Naphthylamide (PAβN) Permeabilizes the Outer Membrane of Gram-Negative Bacteria

  2013cited by this paper
• Microbe-Host Interactions: Structure and Role of Gram-Negative Bacterial Porins

  2012cited by this paper
• Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.

  2012cited by this paper
• Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs

  2012cited by this paper
• Efflux-Mediated Drug Resistance in Bacteria

  2012cited by this paper
• Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery.

  2012cited by this paper
• Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers.

  2012cited by this paper
• Challenges of Antibacterial Discovery

  2011cited by this paper
• Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.

  2011cited by this paper
• Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily.

  2011cited by this paper
• Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori.

  2010cited by this paper
• In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli

  2010cited by this paper
• The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus.

  2010cited by this paper
• Liposomes as delivery systems for antibiotics.

  2010cited by this paper
• Siderophore uptake in bacteria and the battle for iron with the host; a bird’s eye view

  2010cited by this paper
• The bacterial cell envelope.

  2010cited by this paper
• CHAPTER 3 – The problem of resistance

  2010cited by this paper
• Wall Teichoic Acid Function, Biosynthesis, and Inhibition

  2009cited by this paper
• Synthesis of citrate-ciprofloxacin conjugates.

  2009cited by this paper
• Outer membrane permeability and antibiotic resistance.

  2009cited by this paper
• Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth

  2009cited by this paper
• Efflux-Mediated Drug Resistance in Bacteria

  2009cited by this paper
• Peptidoglycan structure and architecture.

  2008cited by this paper
• The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria

  2008cited by this paper
• Direct Visualization of the Outer Membrane of Mycobacteria and Corynebacteria in Their Native State

  2008cited by this paper
• Cell wall peptidoglycan architecture in Bacillus subtilis

  2008cited by this paper
• Cell envelope stress response in Gram-positive bacteria.

  2008cited by this paper
• Physicochemical properties of antibacterial compounds: implications for drug discovery.

  2008cited by this paper
• The role of iron in Mycobacterium smegmatis biofilm formation: the exochelin siderophore is essential in limiting iron conditions for biofilm formation but not for planktonic growth

  2007cited by this paper
• Porins Are Required for Uptake of Phosphates by Mycobacterium smegmatis

  2007cited by this paper
• MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.

  2007cited by this paper
• Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux.

  2006cited by this paper
• Multidrug-resistance efflux pumps ? not just for resistance

  2006cited by this paper
• Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

  2006cited by this paper
• Wall Teichoic Acid Polymers Are Dispensable for Cell Viability in Bacillus subtilis

  2006cited by this paper
• The growth rate of Mycobacterium smegmatis depends on sufficient porin‐mediated influx of nutrients

  2005cited by this paper
• Selected Arylpiperazines Are Capable of Reversing Multidrug Resistance in Escherichia coli Overexpressing RND Efflux Pumps

  2005cited by this paper
• Bacterial efflux systems and efflux pumps inhibitors.

  2005cited by this paper
• Inhibitors of efflux pumps in Gram-negative bacteria.

  2005cited by this paper
• Bacterial resistance to antibiotics: active efflux and reduced uptake.

  2005influential reference
• Inhibition of Antibiotic Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors Biricodar (VX-710) and Timcodar (VX-853)

  2004cited by this paper
• Time-related differences in the physical property profiles of oral drugs.

  2004cited by this paper
• Lipoprotein trafficking in Escherichia coli

  2004cited by this paper
• Multidrug efflux systems in Gram-negative bacteria

  2004cited by this paper
• A Continuum of Anionic Charge: Structures and Functions of d-Alanyl-Teichoic Acids in Gram-Positive Bacteria

  2003cited by this paper
• The efflux pump inhibitor Phe-Arg-beta-naphthylamide does not abolish the activity of the Stenotrophomonas maltophilia SmeDEF multidrug efflux pump.

  2003cited by this paper
• MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization.

  2003cited by this paper
• Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria.

  2002cited by this paper
• Cellular impermeability and uptake of biocides and antibiotics in Gram‐positive bacteria and mycobacteria

  2002cited by this paper
• Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative bacterial pathogens?

  2002cited by this paper
• Efflux-mediated drug resistance in Gram-positive bacteria.

  2001cited by this paper
• Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria.

  2001cited by this paper
• MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis

  2001cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy

  2001cited by this paper
• Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications.

  2000cited by this paper
• Stages of Polymyxin B Interaction with theEscherichia coli Cell Envelope

  2000cited by this paper
• Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.

  1999cited by this paper
• Structures of Gram-Negative Cell Walls and Their Derived Membrane Vesicles

  1999cited by this paper
• Surface Proteins of Gram-Positive Bacteria and Mechanisms of Their Targeting to the Cell Wall Envelope

  1999cited by this paper
• Microbial genome analyses: global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities.

  1998cited by this paper

• Hybrid Nano-Bio Platforms: Synergistic Strategies Combining Probiotic Metabolites and Nanocarriers Against Multidrug-Resistant Pathogens

  2025cites this paper
• An Overview of Drugging the Bacterial Cytoskeleton, Rod, and Divisome Systems.

  2025cites this paper
• Technological developments driving industrial natural product discovery.

  2025cites this paper
• Rationally designed photosensitizers with enhanced spin-orbit coupling for high quantum yield and potent antibacterial activity.

  2025cites this paper
• Navigating Antibiotic Resistance in Gram-Negative Bacteria: Current Challenges and Emerging Therapeutic Strategies.

  2025cites this paper
• Cas9 modulates Campylobacter jejuni virulence traits inside intestinal epithelial cells

  2025cites this paper
• Cellular evaluation of superoxide dismutase mimics as catalytic drugs: Challenges and opportunities

  2024cites this paper
• Benzothiazole DNA gyrase inhibitors and their conjugates with siderophore mimics: design, synthesis and evaluation

  2024cites this paper
• Characterization of Dichloroisoeverninic Acid Biosynthesis and Chemoenzymatic Synthesis of New Orthosomycins.

  2024cites this paper
• A solution NMR methodology enabling the elucidation of small molecule phospholipid membrane adhesion and passive permeation parameters.

  2024cites this paper
• New N-phenylpyrrolamide inhibitors of DNA gyrase with improved antibacterial activity

  2024cites this paper
• Improved N-phenylpyrrolamide inhibitors of DNA gyrase as antibacterial agents for high-priority bacterial strains.

  2024cites this paper
• Estimation of passive gastrointestinal absorption of new dual DNA gyrase and topoisomerase IV inhibitors using PAMPA and biopartitioning micellar chromatography and quantitative structure-retention relationship analysis.

  2024cites this paper
• Modulating mycobacterial envelope integrity for antibiotic synergy with benzothiazoles

  2024cites this paper
• A Novel Two-Component Bacteriocin, Acidicin P, and Its Key Residues for Inhibiting Listeria monocytogenes by Targeting the Cell Membrane

  2023cites this paper
• Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens

  2023cites this paper
• Bactericidal activity of silver nanoparticles in drug-resistant bacteria

  2023cites this paper
• Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant Mycobacterium tuberculosis

  2022cites this paper
• Discovery of Inhibitors of the Lipopolysaccharide Transporter MsbA: From a Screening Hit to Potent Wild-Type Gram-Negative Activity.

  2022cites this paper
• Restricting Bond Rotations by Ring Fusion: A Novel Molecular Design Strategy to Improve Photodynamic Antibacterial Efficacy of AIE Photosensitizers.

  2022cites this paper
• Caging Pyrophosphate Structure Blocks the Cell Wall Synthesis to Kill Bacteria without Detectable Resistance

  2022cites this paper
• Evaluation of Antimicrobial and Proliferation of Fibroblast Cells Activities of Citrus Essential Oils

  2022cites this paper
• Synthesis and structure-activity relationship studies of original cyclic diadenosine derivatives as nanomolar inhibitors of NAD kinase from pathogenic bacteria.

  2022cites this paper
• Aminoacyl-tRNA Synthetases as Valuable Targets for Antimicrobial Drug Discovery

  2021cites this paper
• Chemical Components and Antibacterial Activity of Essential Oil Extracted from Citrus x aurantifolia Peel

  2021cites this paper
• Opportunities and Challenges of Bacterial Glycosylation for the Development of Novel Antibacterial Strategies

  2021cites this paper
• A Novel Antimicrobial Peptides From Pine Needles of Pinus densiflora Sieb. et Zucc. Against Foodborne Bacteria

  2021cites this paper
• Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls

  2020cites this paper
• Nano/Microparticles Encapsulation Via Covalent Drug Conjugation

  2020cites this paper
• Discovery of Pyrido[2,3-b]indole Derivatives with Gram-negative Activity Targeting Both DNA Gyrase and Topoisomerase IV.

  2020cites this paper
• Induction of Antibacterial Metabolites by Co-Cultivation of Two Red-Sea-Sponge-Associated Actinomycetes Micromonospora sp. UR56 and Actinokinespora sp. EG49

  2020cites this paper
• Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies

  2019cites this paper
• Design, synthesis and biological evaluation of novel DNA gyrase inhibitors and their siderophore mimic conjugates.

  2019cites this paper
• Antibacterial Effect and Mode of Action of Flavonoids From Licorice Against Methicillin-Resistant Staphylococcus aureus

  2019cites this paper
• Siderophore–Antibiotic Conjugate Design: New Drugs for Bad Bugs?

  2019cites this paper
• Natural flavones from Morus alba against MRSA via targeting the proton motive force and membrane permeability.

  2019cites this paper
• The Concept of an Ideal Antibiotic: Implications for Drug Design

  2019cites this paper
• An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.

  2019cites this paper
• Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

  2018cites this paper
• Reaching toward underexplored targets in antibacterial drug design

  2018cites this paper
• Synthesis and antimicrobial evolution of some new benzotriazole substituted 1,3,4-thiadiazoles

  2018cites this paper
• Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance

  2018cites this paper
• Refining the structure−activity relationships of 2-phenylcyclopropane carboxylic acids as inhibitors of O-acetylserine sulfhydrylase isoforms

  2018cites this paper